ХРОНИЧЕСКИЙ ГЕПАТИТ В И ПРОБЛЕМА ПЕРСИСТЕНЦИИ ВИРУСА С ПОЗИЦИЙ ИММУНОПАТОГЕНЕЗА ЗАБОЛЕВАНИЯ


Цитировать

Полный текст

Аннотация

В обзоре представлены результаты последних исследований, касающихся проблемы персистенции вируса гепатита В. Рассмотрены различные механизмы формирования хронической формы инфекции с позиции иммунопатогенеза заболевания. Обсуждаются данные, полученные при изучении генетических особенностей вируса гепатита В и формирования его мутантных форм, значение апоптоза как фундаментального процесса гомеостаза, роль HLA-рестриктированного Т-клеточного ответа и цитокинов при разрешившейся и персистентной форме инфекции, вызванной вирусом гепатита В.

Полный текст

ХРОНИЧЕСКИЙ ГЕПАТИТ В И ПРОБЛЕМА ПЕРСИСТЕНЦИИ ВИРУСА С ПОЗИЦИЙ ИММУНОПАТОГЕНЕЗА ЗАБОЛЕВАНИЯ
×

Об авторах

Т. А Семененко

НИИ эпидемиологии и микробиологии им. Н.Ф.Гамалеи, Москва

Список литературы

  1. Семененко Т.А. Иммунологические показатели эффективности лечения хронического гепатита. Вирусные гепатиты. 2005, 1: 3-8.
  2. Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты. М., ГОУ ВУНМЦ МЗ РФ, 2003.
  3. Barnes E., Ward S.M., Kasprowicz V.O. et al. Ultrasensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur. J. Immunol. 2004, 34 (6):1570-1577.
  4. Baumert T.F., Barth H., Blum H.E. Genetic variants of hepatitis B virus and their clinical relevance. Minerva Gastroenterol. Dietol. 2005, 51: 95-108.
  5. Baumert T.F., Thimme R., F. von Weizs cker F. Pathogenesis of hepatitis B virus infection. World J. Gastroenterol. 2007, 13 (1): 82-90.
  6. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J. Gen. Virol. 2006, 87: 1439-1449.
  7. Bortolami M., Kotsafti A., Cardin R. et al. Fas/FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J. Viral. Hepat. 2008, 15 (7):515-522.
  8. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004, 127: S56–S61.
  9. Chang J.J, Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell. Biol. 2007, 85 (1): 16-23.
  10. Chichester J.A., Feitelson M.A., Calkins C.E. Transient inhibition of Th1-type cytokine production by CD4 T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells. Immunology. 2006, 118 (4): 438-448.
  11. Cooksley H., Chokshi S., Maayan Y. et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob. Agents Chemother. 2008, 52 (1):312-320.
  12. Ganem D., Prince A.M. Hepatitis B virus infectionnatural history and clinical consequences. N. Engl. J. Med. 2004, 350: 1118-1129.
  13. Glebe D. Recent advances in hepatitis B virus research: A German point of view. World J. Gastroenterol. 2007,13 (1): 8-13.
  14. Glebe D., Urban S. Viral and cellular determinants involved in hepadnoviral entry. Ibid.: 22-38.
  15. Grayson J.M., Weant A.E., Holbrook B.C. et al. Role of Bim in regulating CD8+ T-cell responses during chronic viral infection. J. Virol. 2006. 80 (17): 8627- 8638.
  16. Han Y.N., Yang J.L., Zheng S.G. еt al. Relationship of human leukocyte antigen class II genes with the susceptibility to hepatitis B virus infection and the response to interferon in HBV-infected patients. World J. Gastroenterol. 2005, 11 (36): 5721-5724.
  17. Hui C.K., Lau G.K. Immune system and hepatitis B virus infection. J. Clin. Virol. 2005, 34 (1): S44-48.
  18. Hwang Y.K., Kim N.K., Park J.M. et al. HLA-A2 1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine. 2002, 20: 3770–3777.
  19. Kakimi K., Isogawa M., Chung J. et al. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 2002, 76: 8609–8620.
  20. Kim K.H., Seong B.L. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J. 2003, 22: 2104-2116.
  21. Leistner C.M., Gruen-Bernhard S., Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell. Microbiol. 2008, 10 (1): 122-133.
  22. Mizukoshi E., Sidney J., Livingston B. et al. Cellular immune responses to the hepatitis B virus polymerase. J. Immunol. 2004, 173: 5863–5871.
  23. Norder H., Courouce A., Coursaget P. et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes and HBsAg subtypes. Intervirology. 2004, 47 (6): 289-309.
  24. Pawlotsky J.M. The concept of hepatitis B virus mutant escape. J. Clin. Virol. 2005, 34 (1): S125-S129.
  25. Peng G., Li S., Wu W. et al. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008, 123 (1): 57-65.
  26. Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Sem. Liv. Dis. 2007, 27 (2): 152-160.
  27. Reignat S., Webster G.J., Brown D. et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J. Exp. Med. 2002, 195: 1089-1101.
  28. Ren F.Y., Jin H., Piao X.X. Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B. World J. Gastroenterol. 2007, 13 (41): 5440-5445.
  29. Rushbrook S.M., Hoare M., Alexander G.J. T-regulatory lymphocytes and chronic viral hepatitis. Expert. Opin. Biol. Ther. 2007, 7 (11): 1689-1703.
  30. Schildgen O., Sirma H., Funk A. et al. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 2006, 354: 1807-1812.
  31. Sprengers D., van der Molen R.G., Kusters J.G. et al. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J. Hepatol. 2006, 45: 182-189.
  32. Su F., Theodosis C.N, Schneider R.J. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J. Virol. 2001, 75: 215-225.
  33. Thimme R., Wieland S., Steiger C. et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. Ibid. 2003, 77: 68-76.
  34. Thio C.L., Thomas D.L., Karacki P. et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. Ibid.: 12083– 12087.
  35. van der Molen R.G., Sprengers D., Binda R.S. et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 2004, 40: 738–746.
  36. Urbani S., Boni C., Amadei B. et al. Acute phase HBVspecific T cell responses associated with HBV persistence after HBV/HCV coinfection. Ibid. 2005, 41: 826–831.
  37. Weant A.E., Michalek R.D., Khan I.U. еt al. Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity. 2008, 28 (2): 218-230.
  38. Webster G.J., Reignat S., Brown D. et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 2004, 78: 5707–5719.
  39. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. Ibid. 2005, 79: 9369-9380.
  40. Xu D., Fu J., Jin L. et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 2006, 177 (1):739-747.
  41. Yang G., Liu J., Han S. et al. Association between hepatitis B virus infection and HLA-DRB1 genotyping in Shaanxi Han patients in northwestern China. Tissue Antigens. 2007, 69 (2): 170-175.
  42. You J., Sriplung H., Geater A. et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J. Gastroenterol. 2008, 14 (7): 1112-1119.
  43. Zhu X.L., Du T., Li J.H. еt al. Association of HLA-DQB1 gene polymorphisms with outcomes of HBV infection in Chinese Han population. Swiss. Med. Wkly. 2007, 137 (7—8): 114-120.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Семененко Т.А., 2009

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах